Works matching DE "ATEZOLIZUMAB"

Results: 370
    1
    2
    3
    4

    Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program.

    Published in:
    Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-40569-9
    By:
    • de Moura, Alexandre;
    • Vuagnat, Perrine;
    • Renouf, Benjamin;
    • Pierga, Jean-Yves;
    • Loirat, Delphine;
    • Vaflard, Pauline;
    • Lafayolle de la Bruyère, Charline;
    • Chaumard-Billotey, Natacha;
    • Hajjaji, Nawale;
    • Ladoire, Sylvain;
    • Dabakuyo, Sandrine;
    • Patsouris, Anne;
    • Frenel, Jean Sébastien;
    • Nicolai, Vincent;
    • Alexandre, Marie;
    • Dohollou, Nadine;
    • Grenier, Julien;
    • Bourien, Heloïse;
    • Bidard, François-Clément
    Publication type:
    Article
    5

    Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program.

    Published in:
    Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-40569-9
    By:
    • de Moura, Alexandre;
    • Vuagnat, Perrine;
    • Renouf, Benjamin;
    • Pierga, Jean-Yves;
    • Loirat, Delphine;
    • Vaflard, Pauline;
    • Lafayolle de la Bruyère, Charline;
    • Chaumard-Billotey, Natacha;
    • Hajjaji, Nawale;
    • Ladoire, Sylvain;
    • Dabakuyo, Sandrine;
    • Patsouris, Anne;
    • Frenel, Jean Sébastien;
    • Nicolai, Vincent;
    • Alexandre, Marie;
    • Dohollou, Nadine;
    • Grenier, Julien;
    • Bourien, Heloïse;
    • Bidard, François-Clément
    Publication type:
    Article
    6

    Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using computed tomography in HCC patients.

    Published in:
    Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-38377-2
    By:
    • Kondo, Takayuki;
    • Fujiwara, Kisako;
    • Nakagawa, Miyuki;
    • Fujimoto, Kentaro;
    • Yumita, Sae;
    • Ishino, Takamasa;
    • Ogawa, Keita;
    • Iwanaga, Terunao;
    • Koroki, Keisuke;
    • Kanzaki, Hiroaki;
    • Inoue, Masanori;
    • Kobayashi, Kazufumi;
    • Kiyono, Soichiro;
    • Nakamura, Masato;
    • Kanogawa, Naoya;
    • Ogasawara, Sadahisa;
    • Nakamoto, Shingo;
    • Chiba, Tetsuhiro;
    • Kato, Jun;
    • Kato, Naoya
    Publication type:
    Article
    7
    8
    9
    10
    11
    12

    Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.

    Published in:
    Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-45798-8
    By:
    • Hieken, Tina J.;
    • Nelson, Garth D.;
    • Flotte, Thomas J.;
    • Grewal, Eric P.;
    • Chen, Jun;
    • McWilliams, Robert R.;
    • Kottschade, Lisa A.;
    • Yang, Lu;
    • Domingo-Musibay, Evidio;
    • Dronca, Roxana S.;
    • Yan, Yiyi;
    • Markovic, Svetomir N.;
    • Dimou, Anastasios;
    • Montane, Heather N.;
    • Erskine, Courtney L.;
    • Piltin, Mara A.;
    • Price, Daniel L.;
    • Khariwala, Samir S.;
    • Hui, Jane;
    • Strand, Carrie A.
    Publication type:
    Article
    13

    PD-1<sup>-</sup> CD45RA<sup>+</sup> effector-memory CD8 T cells and CXCL10<sup>+</sup> macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma.

    Published in:
    Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-43381-1
    By:
    • Cappuyns, Sarah;
    • Philips, Gino;
    • Vandecaveye, Vincent;
    • Boeckx, Bram;
    • Schepers, Rogier;
    • Van Brussel, Thomas;
    • Arijs, Ingrid;
    • Mechels, Aurelie;
    • Bassez, Ayse;
    • Lodi, Francesca;
    • Jaekers, Joris;
    • Topal, Halit;
    • Topal, Baki;
    • Bricard, Orian;
    • Qian, Junbin;
    • Van Cutsem, Eric;
    • Verslype, Chris;
    • Lambrechts, Diether;
    • Dekervel, Jeroen
    Publication type:
    Article
    14

    Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial.

    Published in:
    Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-40813-w
    By:
    • Monjazeb, Arta M.;
    • Daly, Megan E.;
    • Luxardi, Guillaume;
    • Maverakis, Emanual;
    • Merleev, Alexander A.;
    • Marusina, Alina I.;
    • Borowsky, Alexander;
    • Mirhadi, Amin;
    • Shiao, Stephen L.;
    • Beckett, Laurel;
    • Chen, Shuai;
    • Eastham, David;
    • Li, Tianhong;
    • Vick, Logan V.;
    • McGee, Heather M.;
    • Lara, Frances;
    • Garcia, Leslie;
    • Morris, Leigh Anne;
    • Canter, Robert J.;
    • Riess, Jonathan W.
    Publication type:
    Article
    15

    Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial.

    Published in:
    Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-40813-w
    By:
    • Monjazeb, Arta M.;
    • Daly, Megan E.;
    • Luxardi, Guillaume;
    • Maverakis, Emanual;
    • Merleev, Alexander A.;
    • Marusina, Alina I.;
    • Borowsky, Alexander;
    • Mirhadi, Amin;
    • Shiao, Stephen L.;
    • Beckett, Laurel;
    • Chen, Shuai;
    • Eastham, David;
    • Li, Tianhong;
    • Vick, Logan V.;
    • McGee, Heather M.;
    • Lara, Frances;
    • Garcia, Leslie;
    • Morris, Leigh Anne;
    • Canter, Robert J.;
    • Riess, Jonathan W.
    Publication type:
    Article
    16
    17
    18

    Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study.

    Published in:
    PLoS ONE, 2024, v. 19, n. 1, p. 1, doi. 10.1371/journal.pone.0294590
    By:
    • Kai, Machiko;
    • Hikita, Hayato;
    • Kazuki, Maesaka;
    • Tahata, Yuki;
    • Shinkai, Kazuma;
    • Doi, Akira;
    • Ohkawa, Kazuyoshi;
    • Miyazaki, Masanori;
    • Ishida, Hisashi;
    • Matsumoto, Kengo;
    • Nozaki, Yasutoshi;
    • Yakushijin, Takayuki;
    • Sakamori, Ryotaro;
    • Kaneko, Akira;
    • Iio, Sadaharu;
    • Nawa, Takatoshi;
    • Kakita, Naruyasu;
    • Morishita, Naoki;
    • Hiramatsu, Naoki;
    • Usui, Takeo
    Publication type:
    Article
    19
    20
    21
    22
    23

    Fixed drug eruption from atezolizumab.

    Published in:
    Dermatology Online Journal, 2022, v. 28, n. 1, p. 1, doi. 10.5070/D328157064
    By:
    • Kearns, Donovan;
    • Gardner II, Jeffrey T.;
    • Kerstetter, Justin;
    • Furukawa, Betsy
    Publication type:
    Article
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39

    Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.

    Published in:
    Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2022.1080729
    By:
    • Satoshi Wasamoto;
    • Hisao Imai;
    • Takeshi Tsuda;
    • Yoshiaki Nagai;
    • Hiroyuki Minemura;
    • Yutaka Yamada;
    • Yukihiro Umeda;
    • Takayuki Kishikawa;
    • Ayako Shiono;
    • Yuki Kozu;
    • Jun Shiihara;
    • Ou Yamaguchi;
    • Atsuto Mouri;
    • Kyoichi Kaira;
    • Kenya Kanazawa;
    • Hirokazu Taniguchi;
    • Takayuki Kaburagi;
    • Koichi Minato;
    • Hiroshi Kagamu
    Publication type:
    Article
    40
    41
    42
    43
    44

    Definition of a new blood cell count score for early survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of four multicenter clinical trials.

    Published in:
    Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.961926
    By:
    • Jian-Guo Zhou;
    • Ada Hang-Heng Wong;
    • Haitao Wang;
    • Su-Han Jin;
    • Fangya Tan;
    • Yu-Zhong Chen;
    • Si-Si He;
    • Gang Shen;
    • Frey, Benjamin;
    • Fietkau, Rainer;
    • Hecht, Markus;
    • Carr, Shamus R.;
    • Ruihong Wang;
    • Bo Shen;
    • Schrump, David S.;
    • Hu Ma;
    • Gaipl, Udo S.
    Publication type:
    Article
    45
    46
    47
    48
    49
    50